“Global Rheumatoid Arthritis Drugs market estimated to grow at a CAGR of 0.6% in the second half of the forecast period” says Visiongain report

17 February 2020
Pharma

Visiongain has launched a new pharma report Rheumatoid Arthritis Drugs Market Report: Biologics, Non-Biologics, NSAIDs, sDMARDs and Others.

Demand for RA drugs is on the rise, particularly in developing countries. The TNF inhibitors, which have dominated the market so successfully, are now coming to the end of their patents, opening the way for new biologics and biosimilars to compete for their share of the market. Following the launch of Xeljanz there are other oral DMARDs in development which could potentially undermine the role of the biologics. Changes in the next few years will be critical in determining the future treatment for RA.

The lead analyst of the report commented "Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease. Molecules such as TNFα, interleukin 6, interleukin 1, and janus kinase have all enabled the development of new treatments to target these molecules. As more molecules are identified, and as more is understood about the disease, this will allow new treatments to be explored, and new drugs to be marketed."

Leading companies featured in the report include AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, Johnson & Johnson, Merck & Co, Novartis, Pfizer, Roche, Sanofi, UCB

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes European Antibiotics Market Report 2021-2031

Penicillin segment holds majority of the market share owing to maximum prescription as well as the most generic manufacturers throughout the industry.

22 June 2021

Read

Visiongain Publishes Companion Diagnostics (CDx) Market Report 2021-2031

Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy.

17 June 2021

Read

Visiongain Publishes Cellular Immunotherapy Market Report 2021-2031

Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.

15 June 2021

Read

Visiongain Publishes Gene Therapy R&D Market Report 2021-2031

Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.

14 June 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever